Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Accumulated Expenses (2016 - 2025)

Ligand Pharmaceuticals' Accumulated Expenses history spans 15 years, with the latest figure at $27.9 million for Q4 2024.

  • For Q4 2024, Accumulated Expenses rose 123.84% year-over-year to $27.9 million; the TTM value through Dec 2024 reached $27.9 million, up 123.84%, while the annual FY2024 figure was $27.9 million, 123.84% up from the prior year.
  • Accumulated Expenses for Q4 2024 was $27.9 million at Ligand Pharmaceuticals, up from $15.6 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $27.9 million in Q4 2024 and bottomed at $7.3 million in Q2 2023.
  • The 5-year median for Accumulated Expenses is $14.6 million (2022), against an average of $14.8 million.
  • The largest annual shift saw Accumulated Expenses crashed 49.89% in 2023 before it skyrocketed 123.84% in 2024.
  • A 5-year view of Accumulated Expenses shows it stood at $18.5 million in 2020, then dropped by 5.13% to $17.6 million in 2021, then decreased by 10.8% to $15.7 million in 2022, then dropped by 20.5% to $12.5 million in 2023, then skyrocketed by 123.84% to $27.9 million in 2024.
  • Per Business Quant, the three most recent readings for LGND's Accumulated Expenses are $27.9 million (Q4 2024), $15.6 million (Q3 2024), and $12.2 million (Q2 2024).